Adrian Bloor, MD

Christie Hospital NHS Trust
Manchester, United Kingdom

n/a

Presentation(s):

• (1554106) Stopping ibrutinib after 6 years of continuous exposure results in decreased or stable CLL levels for at least a year in most patients, providing further support for the STATIC trial evaluating intermittent BTKi treatment.

  Sunday, October 8, 2023
  9:45 AM – 9:55 AM EDT